Full-Time

Senior Director

Translational Medicine

Confirmed live in the last 24 hours

Revolution Medicines

Revolution Medicines

201-500 employees

Develops targeted therapies for RAS-driven cancers

Biotechnology
Healthcare

Compensation Overview

$235k - $281kAnnually

Senior, Expert

San Carlos, CA, USA

Hybrid position requiring in-office presence.

Category
Physicians & Surgeons
Medical, Clinical & Veterinary
Requirements
  • A Ph.D. in cancer biology, cell/molecular biology, genomics or equivalent with 10+ years of industry experience.
  • 6+ years of experience in clinical biomarker development in oncology is required.
  • Broad knowledge and understanding of established and novel technologies employed in clinical diagnostic assays (e.g. NGS, IHC, PCR) are required.
  • Excellent scientific and business communication skills, strong interpersonal/collaboration skills and planning skills.
  • Ability to think critically and creatively and be able to work independently to determine appropriate resources for resolution of problems.
  • Ability to multi-task and thrive in a fast-paced innovative environment.
  • A great teammate, who listens effectively and invites response and discussion.
  • Commitment to Revolution Medicines’ Core Values: Tireless Commitment to Patients, Transformative Science, Exceptional Together, Total Integrity, Inclusiveness and Fairness.
Responsibilities
  • Lead strategic, translational thinking and contributions to early and late-stage clinical development plans.
  • Represent Translational Medicine function on cross-functional teams at program level.
  • Effectively collaborate with Clinical Development, Clinical Operations, Biostatistics, Biomarker Operations, and Regulatory on study design and protocol development.
  • Lead biomarker scientists in formulating clinical biomarker strategies and partner with clinical bioinformaticians in developing biomarker analysis plans, as well as effectively collaborate with TM subfunctions of Biomarker Operations, Clinical Bioinformatics, and Companion Diagnostics.
  • Collaborate with Clinical Development, Biostatistics, and Medical Affairs to develop plans for publication of clinical biomarker results.
  • Collaborate with Cancer Biology, Translational Research, and Cancer Immunology to accelerate forward and reverse translational research.
  • Keep abreast in new developments in RAS biology, predictive biomarkers, and novel molecular assays, and share knowledge with functional and cross-functional team members.

Revolution Medicines develops treatments specifically for cancers caused by RAS gene mutations, which are common in difficult-to-treat cancers like pancreatic, colorectal, and lung cancers. Their main product line includes RASON Inhibitors, designed to target and inhibit RAS proteins that contribute to cancer growth. The company uses a Tri Complex Inhibitor platform to create these specialized therapies. Unlike many competitors, Revolution Medicines focuses solely on RAS-driven cancers, allowing them to carve out a niche in the oncology market. Their goal is to transform cancer treatment by providing effective targeted therapies for patients suffering from these challenging conditions.

Company Stage

IPO

Total Funding

$219.8M

Headquarters

Redwood City, California

Founded

2014

Growth & Insights
Headcount

6 month growth

15%

1 year growth

42%

2 year growth

137%
Simplify Jobs

Simplify's Take

What believers are saying

  • The acquisition of EQRx is expected to add over $1 billion in net cash, significantly bolstering Revolution Medicines' financial position.
  • Successful public offerings and underwriters' full exercise of options have brought substantial capital, indicating strong investor confidence.
  • The company's innovative RASON Inhibitors and Tri Complex Inhibitor platform have the potential to revolutionize treatment for RAS-driven cancers, offering significant clinical impact.

What critics are saying

  • The highly specialized focus on RAS-driven cancers may limit market size and revenue potential compared to broader oncology companies.
  • Integration challenges from the acquisition of EQRx could divert focus and resources, potentially impacting ongoing projects.

What makes Revolution Medicines unique

  • Revolution Medicines focuses exclusively on RAS-driven cancers, a niche but critical area in oncology, unlike broader-spectrum oncology companies.
  • Their Tri Complex Inhibitor platform allows for highly specialized treatments, setting them apart from competitors with more generalized approaches.
  • The company's revenue model, which includes licensing, co-development partnerships, and direct sales, provides multiple revenue streams, enhancing financial stability.

Help us improve and share your feedback! Did you find this helpful?